Literature DB >> 32224150

Immunogenicity and safety of influenza vaccination in cancer patients receiving checkpoint inhibitors targeting PD-1 or PD-L1.

A Bayle1, M Khettab2, F Lucibello3, A N Chamseddine4, V Goldschmidt5, A Perret6, S Ropert7, F Scotté8, P Loulergue9, O Mir10.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32224150     DOI： 10.1016/j.annonc.2020.03.290

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  11 in total

1.  PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine.

Authors:  Ramin Sedaghat Herati; David A Knorr; Laura A Vella; Luisa Victoria Silva; Lakshmi Chilukuri; Sokratis A Apostolidis; Alexander C Huang; Alexander Muselman; Sasikanth Manne; Oliva Kuthuru; Ryan P Staupe; Sharon A Adamski; Senthil Kannan; Raj K Kurupati; Hildegund C J Ertl; Jeffrey L Wong; Stylianos Bournazos; Suzanne McGettigan; Lynn M Schuchter; Ritesh R Kotecha; Samuel A Funt; Martin H Voss; Robert J Motzer; Chung-Han Lee; Dean F Bajorin; Tara C Mitchell; Jeffrey V Ravetch; E John Wherry
Journal:  Nat Immunol       Date:  2022-07-28       Impact factor: 31.250

2.  Safety and Immunogenicity of mRNA Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Lung Cancer Receiving Immune Checkpoint Inhibitors: A Multicenter Observational Study in Japan.

Authors:  Makoto Hibino; Kiyoaki Uryu; Takayuki Takeda; Yusuke Kunimatsu; Shinsuke Shiotsu; Junji Uchino; Soichi Hirai; Tadaaki Yamada; Asuka Okada; Yoshikazu Hasegawa; Osamu Hiranuma; Yusuke Chihara; Riko Kamada; Shunichi Tobe; Kazunari Maeda; Shigeto Horiuchi; Tetsuri Kondo; Koichi Takayama
Journal:  J Thorac Oncol       Date:  2022-06-22       Impact factor: 20.121

3.  INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2).

Authors:  Melissa Bersanelli; Diana Giannarelli; Ugo De Giorgi; Sandro Pignata; Massimo Di Maio; Alberto Clemente; Elena Verzoni; Raffaele Giusti; Marilena Di Napoli; Giuseppe Aprile; Paola Ermacora; Annamaria Catino; Vieri Scotti; Francesca Mazzoni; Pamela Francesca Guglielmini; Antonello Veccia; Marco Maruzzo; Ernesto Rossi; Francesco Grossi; Chiara Casadei; Corrado Ficorella; Vincenzo Montesarchio; Francesco Verderame; Mimma Rizzo; Giorgia Guaitoli; Lucia Fratino; Caterina Accettura; Manlio Mencoboni; Fable Zustovich; Cinzia Baldessari; Saverio Cinieri; Andrea Camerini; Letizia Laera; Mariella Sorarù; Paolo Andrea Zucali; Valentina Guadalupi; Francesco Leonardi; Marcello Tiseo; Michele Tognetto; Francesco Di Costanzo; Carmine Pinto; Giorgia Negrini; Antonio Russo; Maria R Migliorino; Marco Filetti; Sebastiano Buti
Journal:  J Immunother Cancer       Date:  2021-05       Impact factor: 13.751

Review 4.  Immunotherapy use outside clinical trial populations: never say never?

Authors:  K Rzeniewicz; J Larkin; A M Menzies; S Turajlic
Journal:  Ann Oncol       Date:  2021-03-24       Impact factor: 51.769

Review 5.  Immune-checkpoint inhibitors from cancer to COVID‑19: A promising avenue for the treatment of patients with COVID‑19 (Review).

Authors:  Silvia Vivarelli; Luca Falzone; Francesco Torino; Giuseppa Scandurra; Giulia Russo; Roberto Bordonaro; Francesco Pappalardo; Demetrios A Spandidos; Giuseppina Raciti; Massimo Libra
Journal:  Int J Oncol       Date:  2020-12-14       Impact factor: 5.650

6.  Improved survival without increased toxicity with influenza vaccination in cancer patients treated with checkpoint inhibitors.

Authors:  Antonios Valachis; Camilla Rosén; Anthoula Koliadi; Evangelos Digkas; Alice Gustavsson; Andreas Nearchou; Gustav J Ullenhag
Journal:  Oncoimmunology       Date:  2021-02-17       Impact factor: 8.110

7.  SARS-CoV-2 vaccines for cancer patients treated with immunotherapies: Recommendations from the French society for ImmunoTherapy of Cancer (FITC).

Authors:  Marie-Léa Gauci; Clélia Coutzac; Roch Houot; Aurélien Marabelle; Céleste Lebbé
Journal:  Eur J Cancer       Date:  2021-02-18       Impact factor: 9.162

Review 8.  SARS-CoV-2 vaccines for cancer patients: a call to action.

Authors:  Chiara Corti; Edoardo Crimini; Paolo Tarantino; Gabriella Pravettoni; Alexander M M Eggermont; Suzette Delaloge; Giuseppe Curigliano
Journal:  Eur J Cancer       Date:  2021-02-25       Impact factor: 10.002

9.  SEOM clinical guidelines for the prophylaxis of infectious diseases in cancer patients (2021).

Authors:  Isabel Echavarria; J Rafael Carrión Galindo; Jesús Corral; María Pilar Diz Taín; Fernando Henao Carrasco; Vega Iranzo González-Cruz; Xabier Mielgo-Rubio; Teresa Quintanar; Carlos Rivas Corredor; Pedro Pérez Segura
Journal:  Clin Transl Oncol       Date:  2022-03-01       Impact factor: 3.405

10.  Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus.

Authors:  C Buske; M Dreyling; A Alvarez-Larrán; J Apperley; L Arcaini; C Besson; L Bullinger; P Corradini; M Giovanni Della Porta; M Dimopoulos; S D'Sa; H T Eich; R Foà; P Ghia; M G da Silva; J Gribben; R Hajek; C Harrison; M Heuser; B Kiesewetter; J J Kiladjian; N Kröger; P Moreau; J R Passweg; F Peyvandi; D Rea; J-M Ribera; T Robak; J F San-Miguel; V Santini; G Sanz; P Sonneveld; M von Lilienfeld-Toal; C Wendtner; G Pentheroudakis; F Passamonti
Journal:  ESMO Open       Date:  2022-01-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.